Acellera Therapeutics
Acellera Therapeutics' AI technology is most suitable for small molecule drug discovery. The organization has a number of SOTA solutions including generative chemistry with multiparametric optimization, quantum chemistry physics models and prediction of binding affinities and ADMETox properties that integrate into a unified discovery platform called QuantumBind.
AI-Enabled Services:
Research services that use machine learning (ML) algorithms
Research services that use large language models (LLM)
Data services that use ML, LLMs or NLP
Generative chemistry and ML driven optimization for drug discovery
Utilize Acellera Therapeutics'Â AI technologies in the following spaces:
Biology, including target discovery, imaging and HTS
Chemistry, including analytical chemistry, manufacturing and medicinal chemistry
Drug Metabolism, including pharmacokinetics and ADME
Safety, including cardiovascular, pulmonary, neuro and reproductive toxicology